HONG KONG, 14 August 2025 – Zhaoke Ophthalmology Limited
(“Zhaoke Ophthalmology”, “Zhaoke” or the “Company”, SEHK: 6622), a leading
ophthalmic pharmaceutical company, is pleased to announce that the Company has
entered into a distribution and supply agreement for the Indonesia market, for
one of the Company’s core products atropine
Under the terms of the agreement, Zhaoke grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the Product in Indonesia. The Company will receive an upfront payment and is eligible to receive additional milestone payments based on specific achievements.
Earlier
this year, the abbreviated new drug application (“ANDA”) for the 0.01% dose and
the new drug application (“NDA”) for the 0.02% dose of Zhaoke’s Atropine
Sulphate Eye Drops have
Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented, “We are thrilled to enter Indonesia, another new Asian market for us. The partnership with PT Ferron marks a significant step in our global growth journey, and Indonesia presents a substantial opportunity for us to introduce our innovative myopia treatment, Atropine Sulphate Eye Drops, to a new and dynamic patient population. As we expand our presence across Asia and beyond, with regulatory approval potentially on the horizon, we look forward to working closely with our partners to make a meaningful impact in the fight against myopia.”
About Atropine Sulphate Eye Drops (NVK002)
NVK002 is an investigational novel topical ophthalmic solution to control myopia progression in children and adolescents. NVK002 features a proprietary formulation that effectively addresses the instability of low-concentration atropine, providing global intellectual property protection. It is preservative-free with an expected shelf life of over 24 months. According to information from China Insights Consultancy (“CIC”), NVK002 is currently one of the most advanced atropine drug candidates globally for treating myopia progression, targeting the broadest patient group, encompassing children and adolescents aged 3 to 17 years old.
About Myopia Progression Control
Myopia has become a major social issue that affects children and adolescents in China. In the “14th Five-Year National Health Plan” issued by the State Council of the Chinese government, clear instructions have been provided for the prevention and treatment of myopia in children and adolescents, aiming to reduce the overall myopia rate among children and adolescents nationwide by more than 0.5% per year. The Ministry of Education also issued the “Proposal for Parents of Comprehensive Prevention and Control of Myopia in Children and Adolescents”, calling on parents to pay attention to their children’s eye health. According to the World Health Organization and CIC, currently there are approximately 700 million myopia patients in China, among them, 163 million are children and adolescents, who may be able to benefit from NVK002. The Board believes that the potential commercialization of NVK002 will enable the Company to establish a leading position in addressing these significant unmet needs in China.
About PT Ferron Par Pharmaceuticals
PT
Ferron Par Pharmaceuticals, a member of Dexa Group, is a fast-growing
pharmaceutical company that started its operation in 2001.
PT Ferron Par Pharmaceuticals has demonstrated its global competitiveness by exporting products to the United Kingdom since 2008 especially Metformin SR tablets since 2011, Glucient SR tablets to the Netherlands since 2018, and Avamina SR tablets to Poland since 2019.
- End -
